Whistling in the wind

Forum for Applied Research and Public Policy

Volumn 15, Issue 1, 2000, Pages 75-79

  Caulfield, Timothy A ^a,b   Richard Gold, E ^c  

^a Faculty of Medicine and Dentistry   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOTECHNOLOGY; COMMODIFICATION; ETHICS; EUROPE; GENE; GENETICS; GENOME; HUMAN; LEGAL ASPECT; PATENT; UNITED STATES;

BIOTECHNOLOGY; COMMODIFICATION; EUROPE; GENES; GENETIC RESEARCH; GENOME, HUMAN; HUMANS; PATENTS; UNITED STATES;

EID: 0007079775     PISSN: 08878218     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jeremy Rifkin, The Biotech Century (New York: Penguin Putman Inc., 1998), p. 64.
2. Allan Williamson, "Letter: Genome Patenting" Science 278 (5339) (October, 1997), p. 785.
3. Dorothy Nelkin and Lori Andrews, "Homo Economicus: Commercialization of Body Tissue in the Age of Biotechnology," Hastings Center report 28 (3) (September-October, 1998), p. 36.
4. Bartha Maria Knoppers, "Status, Sale and Patenting of Human Genetic Material," Nature Genetics 22 (May 1999), pp. 23-25.
5. Sandy Thomas, "Intellectual Property Rights and the Human Genome," in Timothy Caulfield and Bryn Williams-Jones, eds., The Commercialization of Genetic Research: Ethical, Legal and Policy Issues (New York: Kluwer Academic/Plenum Publishing, 1999), pp. 55-62.
6. E. Richard Gold, "Making Room: Reintegrating Basic Research, Health Policy, and Ethics into Patent Law," in Timothy Caulfield and Bryn Williams-Jones, eds., The Commercialization of Genetic Research, pp. 63-78.
7. E. Richard Gold, "Making Room: Reintegrating Basic Research, Health Policy, and Ethics into Patent Law," The Commercialization of Genetic Research, pp. 63-78 Ibid.
8. See also Knoppers, "Status, Sale and Patenting of Human Genetic Material,"
9. Amy Carroll, "Not Always the Best Medicine: Biotechnology and the Global Impact of U.S. Patent Law," The American University Law Review 44 (1995), pp. 2433-2478.
10. Knoppers, "Status, Sale and Patenting of Human Genetic Material."
11. Tom Wilkie, Perilous Knowledge (London: Faber and Faber, 1993), p.96.
12. British House of Commons, Science and Technology Committee. Third Report: Human Genetics: The Science and Its Consequences (House of Commons, Session 1994-95, July, 1995).
13. See also. Ernst and Young's fourth report on the Canadian biotechnology industry. Canadian Biotech '97: Coming of Age (Ernst and Young, 1997).
14. Alberta Science and Research Authority, The Commercialization of Biotechnology in Alberta (November, 1996).
15. Sandy Thomas et al., "Public-sector patents on human DNA," Nature 388 (6644) (August 21, 1997), p. 709.
16. David Blumenthal, "Withholding Research Results in Academic Life Science: Evidence from a Nation Survey of Faculty," Journal of the American Medical Association 277 (15) (April 16, 1997), pp. 1224-1228.
17. Mildred Cho, "Ethical and Legal Issues in the 21st Century," in Preparing for the Millennium: Laboratory Medicine in the 21st Century, 2nd ed. (Washington, DC: AACC Press, 1998).
18. Gold, "Making Room."
19. Howard Levine, "The Written-Description Requirement of Ux v. Lilly," Nature Biotechnology 16 (January 1998), pp. 87-88.
20. M. Heller and R. Eisenberg, "Can Patents Deter Innovation? The Anticommons in Biomedical Research," Science 280 (5364) (May 1, 1998), pp. 698-701.